{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:06:57Z","timestamp":1789711617555,"version":"4.0.1"},"reference-count":24,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Patients with newly\u2010diagnosed acute myeloid leukemia (ND\u2010AML) derive variable survival benefit from venetoclax (Ven) plus hypomethylating agent (HMA) therapy, and the optimal Ven duration across genetic risk groups remains undefined. Among 540 ND\u2010AML patients receiving Ven\u2010HMA at Mayo Clinic, outcomes were compared across Ven 7\u2010 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200933), 14\u2010 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009117), 21\u2010 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200996), and 28\u2010day (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009294) schedules during Cycle 1 and stratified by ELN 2024 and Mayo genetic risk groups. At a median follow\u2010up of 37.7\u2009months, allogeneic stem cell transplant (ASCT) rates were similar across Ven duration groups (15%, 18%, 18%, and 20% for 7\u2010, 14\u2010, 21\u2010, and 28\u2010day;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.86). Median transplant\u2010censored survival was comparable across Ven durations (13.3, 11.9, 16.8, and 13.2\u2009months for 7, 14, 21, 28\u2009days, respectively;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.65), with outcomes driven by ELN risk (6.3, 11.5, 18.3\u2009months for high, intermediate, low;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01) and Mayo genetic risk (6.9, 17.8\u2009months, not reached;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). Survival was comparable across Ven durations within ELN intermediate\/low\u2010risk and all Mayo risk groups. Among ELN high\u2010risk patients, 14\u2010day Ven was associated with inferior transplant\u2010censored survival compared to 21\u2010 and 28\u2010day schedules (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). Notably, 30\u2010 and 60\u2010day mortality were higher with shorter Ven schedules (7\u2010day: 9%\/18%; 14\u2010day: 7%\/15%) versus 28\u2010day (2%\/6%), which likely reflects treatment selection bias. In ND\u2010AML, no significant difference in transplant\u2010censored survival was observed across the 7\u2010, 14\u2010, 21\u2010, and 28\u2010day Ven schedules; prognosis was determined primarily by Mayo and ELN 2024 genetic risk rather than by Ven duration. Prospective trials are needed to establish risk\u2010adapted Ven dosing strategies.\n                  <\/jats:p>","DOI":"10.1002\/ajh.70500","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:23:15Z","timestamp":1789708995000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax Plus Hypomethylating Agent for 7\u2010 Versus 14\u2010 Versus 21\u2010 Versus 28\u2010Day Cycles in Newly\u2010Diagnosed Acute Myeloid Leukemia:\n                    <scp>ELN<\/scp>\n                    and Mayo Genetic Risk\u2013Stratified Analysis in 540 Patients"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2046-4270","authenticated-orcid":false,"given":"Sudhesh","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8478-3801","authenticated-orcid":false,"given":"Momna","family":"Warraich","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2521-6497","authenticated-orcid":false,"given":"Mahnoor","family":"Fatima","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2619","authenticated-orcid":false,"given":"Kristen","family":"McCullough","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al\u2010Kali","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8404","authenticated-orcid":false,"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7336","authenticated-orcid":false,"given":"Antoine N.","family":"Saliba","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William","family":"Hogan","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-4148","authenticated-orcid":false,"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-1708","authenticated-orcid":false,"given":"James","family":"Foran","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Arana","family":"Yi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Scottsdale Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"7","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo C. D.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long\u2010Term Follow\u2010Up of VIALE\u2010A: Venetoclax and Azacitidine in Chemotherapy\u2010Ineligible Untreated Acute Myeloid Leukemia","volume":"99","author":"Pratz K. W.","year":"2024","journal-title":"American Journal of Hematology"},{"issue":"4","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-022-00668-8","article-title":"Venetoclax Combinations Delay the Time to Deterioration of HRQoL in Unfit Patients With Acute Myeloid Leukemia","volume":"12","author":"Pratz K. W.","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"2","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.27180","article-title":"Venetoclax Duration (14 vs. 21 vs. 28\u2009Days) in Combination With Hypomethylating Agent in Newly Diagnosed Acute Myeloid Leukemia: Comparative Analysis of Response, Toxicity, and Survival","volume":"99","author":"Karrar O.","year":"2024","journal-title":"American Journal of Hematology"},{"issue":"1","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","article-title":"Reduced Venetoclax Exposure to 7\u2009Days vs Standard Exposure With Hypomethylating Agents in Newly Diagnosed AML Patients","volume":"15","author":"Willekens C.","year":"2025","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"e_1_2_11_7_1","first-page":"285","article-title":"Azacitidine in Combination With Shortened Venetoclax Treatment Cycles in Patients With Acute Myeloid Leukemia","volume":"104","author":"Fleischmann M.","year":"2025","journal-title":"Annals of Hematology"},{"issue":"1","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2293512","article-title":"Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients With Acute Myeloid Leukemia","volume":"29","author":"Cui J.","year":"2024","journal-title":"Hematology"},{"issue":"1","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-025-01270-4","article-title":"Venetoclax Schedule in AML: 7 Versus 14 Versus 21 Versus 28\u2009Days","volume":"15","author":"Gangat N.","year":"2025","journal-title":"Blood Cancer Journal"},{"issue":"21","key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic Risk Classification for Adults With AML Receiving Less\u2010Intensive Therapies: The 2024 ELN Recommendations","volume":"144","author":"D\u00f6hner H.","year":"2024","journal-title":"Blood"},{"issue":"2","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.27564","article-title":"Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent","volume":"100","author":"Gangat N.","year":"2025","journal-title":"American Journal of Hematology"},{"issue":"12","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations From an International Expert Panel on Behalf of the ELN","volume":"140","author":"D\u00f6hner H.","year":"2022","journal-title":"Blood"},{"key":"e_1_2_11_13_1","article-title":"OPTI\u2010AML: Prospective Randomized Phase 2 Trial of 28 Versus 14 Day Schedule of Venetoclax and Azacitidine for 2 Cycles in Newly Diagnosed Genomically Agnostic Acute Myeloid Leukemia Patients \u2265\u200960\u2009Years","author":"Borate U.","year":"2026","journal-title":"HemaSphere"},{"issue":"16","key":"e_1_2_11_14_1","article-title":"Venetoclax Duration Outcomes Analysis in MDS\/AML Within a Community Hospital","volume":"43","author":"Williams M.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients With Poor\u2010Risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine","volume":"28","author":"Pollyea D. A.","year":"2022","journal-title":"Clinical Cancer Research"},{"issue":"20","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53\u2010Mutant Acute Myeloid Leukemia With Decitabine and Venetoclax","volume":"127","author":"Kim K.","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16166","article-title":"Venetoclax and Hypomethylating Agents in TP53\u2010Mutated Acute Myeloid Leukemia","volume":"187","author":"Aldoss I.","year":"2019","journal-title":"British Journal of Haematology"},{"issue":"11","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular Patterns of Response and Treatment Failure After Frontline Venetoclax Combinations in Older Patients With AML","volume":"135","author":"DiNardo C. D.","year":"2020","journal-title":"Blood"},{"issue":"13","key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 Mutation on Outcomes After Venetoclax and Azacitidine for Patients With Treatment\u2010na\u00efve Acute Myeloid Leukemia","volume":"28","author":"Konopleva M.","year":"2022","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of Venetoclax and Azacitidine in Treatment\u2010na\u00efve Patients With Acute Myeloid Leukemia and IDH1\/2 Mutations","volume":"28","author":"Pollyea D. A.","year":"2022","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26692","article-title":"Postremission Cytopenia Management in Patients With Acute Myeloid Leukemia Treated With Venetoclax and Azacitidine in VIALE\u2010A","volume":"97","author":"Pratz K. W.","year":"2022","journal-title":"American Journal of Hematology"},{"issue":"18","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184618","article-title":"Venetoclax With Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta\u2010Analysis of Survival Data From Real\u2010World Studies","volume":"15","author":"Ucciero A.","year":"2023","journal-title":"Cancers"},{"key":"e_1_2_11_23_1","article-title":"Prospective NAMLG LD\u2010VenEx Trial: Azacitidine in Combination With Reduced Duration of Venetoclax in Patients With de Novo, Secondary, and Relapsed\/Refractory Acute Myeloid Leukemia","author":"T\u00f8lb\u00f8ll S\u00f8rensen A. L.","year":"2026","journal-title":"HemaSphere"},{"issue":"8","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"E299","DOI":"10.1002\/ajh.26600","article-title":"Timing of Response With Venetoclax Combination Treatment in Patients With Newly Diagnosed Acute Myeloid Leukemia","volume":"97","author":"Jonas B. A.","year":"2022","journal-title":"American Journal of Hematology"},{"issue":"21","key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic Risk Stratification and Outcomes Among Treatment\u2010Naive Patients With AML Treated With Venetoclax and Azacitidine","volume":"144","author":"D\u00f6hner H.","year":"2024","journal-title":"Blood"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70500","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:23:19Z","timestamp":1789708999000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":24,"alternative-id":["10.1002\/ajh.70500"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70500","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"2026-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajh.70500"}}